BioCentury
ARTICLE | Finance

Kadmon maneuvers

Kadmon IPO would mix multiple technology platforms with Waksal reputations

October 6, 2014 7:00 AM UTC

Now that Kadmon Corp. LLC has subtly signaled its interest in the public markets, the key question is whether public investors think the roles of the Waksal brothers in Kadmon add or detract from the biotech's intrinsic value.

The signal came late last month, when Kadmon said it was exploring opportunities, including an IPO. The company named Harlan Waksal, a member of its "board of managers," as president and CEO. Former CEO Samuel Waksal was named chief of innovation, science and strategy...